Overview

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Subjects who have completed study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 µg in study 4975-MN-203 if they meet the inclusion/exclusion criteria.
Phase:
Phase 2
Details
Lead Sponsor:
Centrexion Therapeutics